Hillstream BioPharma, Inc. (NASDAQ:HILS) is currently trading at $1.4602, a gain of over +0.7892 (+117.6155%). The stock prices are surging after Hillstream BioPharma announced a deal with Dana-Farber Cancer Institute to license technology aimed at MUC1-C oncoprotein. The MUC1 gene, discovered by Dr. Donald Kufe at Dana-Farber, is overexpressed in cancer and linked to chronic inflammation.
The MUC1 gene codes for a protein called MUC1 which is found on the surface of many types of cells, including cancer cells. It is involved in several cellular processes, including cell adhesion and signaling, and has been implicated in the development and progression of certain cancers, including breast and pancreatic cancer, due to its overexpression. Research into targeting the MUC1-C oncoprotein, a truncated form of the MUC1 protein, as a potential therapeutic strategy for cancer is ongoing.
HILS above $1.30 seems to be a favorite idea right now. We think HILS could see $2+ today. Good news and high relative volume with lots of range.
Dana-Farber has given Hillstream Biopharma exclusive rights to its technology under an option agreement. If converted to a license, Hillstream will develop anti-MUC1-C antibodies to deliver its lead candidate HSB-1216 and induce ferroptosis in cancer stem cells (CSCs). This combination of HSB-1216 and MUC1-C antibodies is expected to effectively eliminate CSCs for better long-term responses and cures.